Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 4 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Kymera Therapeutics INC paid sponsored hires in similar roles1 certified filing for “Senior Director, Pharmacovigilance Operations” (Regulatory Affairs Managers) in MA: $280k–$280k, median $280k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 4 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Kymera Therapeutics INC paid sponsored hires in similar roles
- 1 certified filing for “Senior Director, Pharmacovigilance Operations” (Regulatory Affairs Managers) in MA: $280k–$280k, median $280k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Who we are:
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn .
How we work:
• PIONEER : We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
• COLLABORATE : We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
• BELONG : We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.
How you’ll make an impact:
• As a program core team member, own early commercial strategy for assigned programs.
• Develop disease and market landscapes covering patient journey, treatment paradigms, unmet needs, stakeholder decision drivers, and sources of market disruption.
• Partner with Clinical Development, Medical, Regulatory, Research, and Program Leadership to shape target product profiles and evidence-generation priorities that drive differentiation.
• Lead indication prioritization and sequencing, weighing scientific rationale, epidemiology, competitive intensity, feasibility, market access, and commercial attractiveness.
• Build market models, revenue forecasts, and risk-adjusted assessments to inform portfolio planning, investment decisions, and long-range planning.
• Design and run primary and secondary market research with physicians, payers, and patients; translate findings into decision-ready recommendations.
• Support evaluation of new targets, pipeline, lifecycle, and business development opportunities through integrated scientific and commercial assessment.
• Maintain a forward-looking view of competitors, mechanisms, clinical programs, and emerging scientific trends relevant to Kymera's portfolio.
• Identify key intelligence questions and competitive scenarios, distinguishing signal from noise and flagging implications for Kymera's programs.
• Deliver concise news-flow updates and landscape syntheses to program teams and leadership, interpreting what changed, why it matters, and what should follow.
• Attend key medical and scientific meetings to capture competitive data, synthesize in real time, and produce post-congress readouts.
• Use Kymera's AI-enabled intelligence tools to accelerate monitoring, triage, and synthesis, while maintaining rigorous source validation and traceability.
• Help improve CI processes, templates, taxonomies, and AI-supported workflows to deliver insights faster with less manual effort.
• Serve as a trusted strategic partner to program teams and functional leaders, bringing an external market and competitor lens into development decisions.
• Translate complex scientific, clinical, and financial information into crisp executive narratives and presentations.
• Frame ambiguous business questions, define the analytical approach, and drive projects to clear decisions.
• Contribute to Corporate Strategy priorities — portfolio strategy, long-range planning, investor analyses — as business needs
Apply on company site ↗